tamfinder.ai

Tamfinder market filing

Global

Nov 21, 2026

BOOTSTRAPPABLE

A full-stack hardware and no-code automation ecosystem replacing custom lab electronics for preclinical neurobiology, drug discovery, and behavioral research laboratories.

TAM // TOTAL ADDRESSABLE MARKET

Low confidence

$480M to $1.1B

SAM // SERVICEABLE ADDRESSABLE MARKET

Low confidence

$96M to $220M

SOM 3YR // SERVICEABLE OBTAINABLE MARKET

$0M

Real pain, real market, but SOM lands below venture threshold given incumbent lock-in and fragmented buyer base

The core insight is sound: preclinical neuro labs waste months on custom electronics that no-code hardware ecosystems could replace. But your SOM of $5.8M over three years sits below the $10M venture threshold, and the path there depends on converting labs that are already embedded in Opentrons, Hamilton, or Tecan workflows with $261M, $1B+, and $42B+ behind them respectively. The single weakest link in your pitch is customer acquisition velocity: the evidence shows only 314–550 identifiable dedicated preclinical institutions globally, most are SMEs or academic labs with constrained capital budgets, and each sale requires hardware validation plus GLP compliance review, compressing your realistic Year-1 close rate to single digits. You need to prove a beachhead segment, likely indie biotech neuro groups, where custom electronics pain is sharpest and procurement cycles are shortest, before this story scales to venture economics.

Key risk

Only 314–550 identifiable preclinical institutions globally limits close rate to single digits in Year 1.

TAM // TOTAL ADDRESSABLE MARKET

Low confidence

$480M to $1.1B

stated: $480M

Preclinical neurobiology and behavioral research automation hardware plus software; a narrow slice of the $8.3B lab automation market, estimated at roughly 5–6% of that total.

Top-down yields $480M by carving preclinical neuro share from lab automation; bottom-up on 12,500 programs at $80K average yields $1.0B–$1.1B. The gap reflects that many preclinical programs share equipment across labs and do not each own a full system.

SAM // SERVICEABLE ADDRESSABLE MARKET

Low confidence

$96M to $220M

stated: $96M

Labs reachable with a no-code hardware-plus-software stack today: English-language-accessible, budget-aware academic and biotech preclinical neuro labs, estimated at 20% of TAM lower bound.

Top-down SAM (20% of $480M) gives $96M; bottom-up SAM (550 reachable labs at $400K lifetime spend over 5 years = $44M/yr, or 2,500 programs at $80K average with 10% reachable = $200M) gives $200M–$220M. Lab-count data is fragmentary, inflating bottom-up; conservative top-down is preferred.

SOM 3YR // SERVICEABLE OBTAINABLE MARKET

$5.8M

Year-3 capture of roughly 6% of conservative SAM, representing approximately 70–75 labs at a blended $75K–$80K per deployment across hardware and first-year software.

>Methodology

TAM TOP-DOWN

Start with the global lab automation market at $8.3B (GrandView, 2024). Neuroscience and behavioral preclinical research is a subset of pharma and academic research verticals. Academic and research segments represent roughly 30–35% of lab automation spend based on academic revenue dominance noted in the evidence. Preclinical neuro and behavioral work is estimated at 15–20% of that research slice, reflecting the broader neuroscience market at $38B but only the research-tools and hardware component, not therapeutics. Applying 17.5% (midpoint) to 33% yields roughly 5.8% of the total market.

$8.3B x 33% research share x 17.5% neuro-behavioral subset = $480M

TAM BOTTOM-UP

Global preclinical pharmaceutical pipeline holds 12,500 programs (Anilocus/GlobalData, 2024). Neuroscience programs represent approximately 10–12% of preclinical pipelines based on neuroscience being one of the larger therapeutic areas. Using 10% yields 1,250 neuro-focused preclinical program-equivalents. Each program-running lab deploys or needs 1 automation system; average system cost is $80K (midpoint of the $20K–$180K evidence range, weighted toward academic/biotech budgets). This is a one-time hardware proxy; annualizing over a 5-year refresh cycle adds software at $15K/yr per lab.

12,500 preclinical programs x 10% neuro share = 1,250 labs x $80K system + $15K software = $1.0B–$1.1B TAM

SAM FILTERS

Filter 1: English-accessible markets with established pharma-biotech ecosystems (US, UK, Germany lead globally): 60% of TAM, justified by concentration of preclinical investment in North America and Western Europe. Filter 2: Labs with budget and mandate for dedicated automation hardware, excluding large pharma with incumbent Tecan or Hamilton contracts: 40% of remainder. Filter 3: No-code positioning narrows to labs without dedicated automation engineers, estimated at 50% of mid-tier academic and biotech labs. Combined: 60% x 40% x 50% = 12% of TAM lower bound.

$480M x 60% geography x 40% budget-fit x 50% no-code fit = $57M–$96M SAM

SOM BUILD

Three-year build: Year 1, 10 labs closed at $75K average blended (hardware plus first-year software) = $750K. Year 2, 25 labs at $78K = $1.95M. Year 3, 40 labs at $80K = $3.2M. Cumulative Year-3 annual run rate: $5.9M, rounded to $5.8M. Share of $96M SAM at Year 3 = 6%, within the realistic 2–8% ceiling. Competitor headwinds from Opentrons ($261M funded, $45M revenue) and emerging AI-lab entrants compress share capture; GLP validation friction adds 3–6 month sales cycles.

10 labs x $75K + 25 labs x $78K + 40 labs x $80K = $5.9M Year-3 run rate; 6% of $96M SAM

Competitors // Threat map

NameFundingPositioningThreat
Opentrons$261M raised; ~$45M annual revenue; $1.8B valuation (2024)Open-source liquid handling robotics at sub-$30K entry price, targeting accessible benchtop automation for research labsHighest direct threat: already owns the price-sensitive academic and biotech lab segment this startup targets, with large installed base and brand recognition.
Lila Sciences$550M raised; valuation exceeds $1.3B (2025)AI-driven autonomous science factories with closed-loop hypothesis generation and robotic execution across life sciences and chemistryMedium threat near-term, high threat in 3–5 years: targets larger enterprise labs but signals where investor dollars are flowing, raising the bar for differentiation.
Medra~$63M total funding; Series A $52M (Dec 2025)Physical AI robotics plus AI reasoning for autonomous cell-culture and liquid-handling, deployed at GenentechMedium threat: targets overlapping drug-discovery automation buyer with a natural-language interface angle, directly competing on the no-code-adjacent value proposition.
Hamilton Company and Tecan GroupTecan CHF 934M in 2024 sales; Hamilton is a Danaher subsidiaryEnterprise-scale liquid handling platforms with deep pharma and CRO relationships, high-precision systems at $100K–$200K+Lower direct threat to the startup's entry segment but dominant in any accounts that scale up; incumbent relationships and service infrastructure are very hard to displace.

Sources

  1. 01Grand View Research: Lab Automation Market Size & Share Report, 2025–2033 · TAM anchor: $8.3B global lab automation market (2024)
  2. 02Polaris Market Research: Lab Automation Market Size, 2025–2034 · TAM corroboration: $7.77B–$8.26B range (2024–2025)
  3. 03MarketsandMarkets: Lab Automation Market, 2026–2031 · TAM corroboration: $6.26B (2025) to $8.62B (2031)
  4. 04Market Research Future: Neuroscience Market Size, 2025–2035 · Neuroscience market sizing context: $38.49B (2025) to $58.76B (2035)
  5. 05MedicalXpress: Decade of Early-Stage Drug Development Shift (2026) · Customer count: 18,999 early-stage drug programs globally in 2024
  6. 06Anilocus: Pharma Drug Market with 12,500+ Preclinical Drugs · Customer count: 12,500 drugs in preclinical development (2024)
  7. 07Spherical Insights: Cognitive Neuroscience Market · Academic research institutes as largest revenue segment in neuroscience market
  8. 08PMC: Preclinical Antibacterial Development Institutions · Institutional count proxy: 314 preclinical R&D institutions (antibacterial alone)
  9. 09Intuition Labs: Lab Automation Companies Compared (Opentrons pricing) · Pricing anchor: Opentrons OT-2 at $15,950; Flex at $24,950
  10. 10LabX: Best Automated Liquid Handling Systems of 2026 · Pricing anchors: Hamilton STAR $100K–$200K+; Biomek i7 $100K–$180K+
  11. 11LabX: Lab Automation Pricing Overview · Pricing range: $20K–$500K+ for new lab automation systems
  12. 12Tracxn: Opentrons Funding and Investors · Competitor profile: Opentrons $261M raised, ~$45M revenue, $1.8B valuation
  13. 13EuTech Future: Lila Sciences $550M Raise · Competitor profile: Lila Sciences $550M funding, $1.3B+ valuation
  14. 14MobiHealthNews: Medra Raises $52M, Partners with Genentech · Competitor profile: Medra $63M total funding, Genentech deployment
  15. 15Future Market Insights: Lab Automation Market (Tecan, Hamilton) · Competitor profile: Tecan CHF 934M 2024 sales; incumbent barriers to entry
  16. 16ArXiv: Standardization in Lab Automation (SiLA, LAPP) · Headwind: interoperability and standardization gaps across lab devices
  17. 17ArXiv: Low-Cost Lab Automation Limitations · Headwind: Opentrons and low-cost options lack integration with existing lab equipment

More filings

Browse all filings →

Size another idea